Slide Just because you can't see something, doesn't mean it's not there.  SEE WHAT'S NEW AT 4D PATH 4D Path’s patented precision oncology platform — which has recently been awarded FDA Breakthrough Device Designation — unveils ​previously hidden data to instantly provide more accurate biomarker profiling ​and stratification directly just from H&E WSI biopsy/resection images. ​By eliminating the need for additional tests (e.g. immunohistochemistry, genetic testing) 4D Path’s cloud-based platform accelerates complete, actionable and objective insight leading to expedited and democratized precision medicine for optimized patient care and clinical trials. ​4D Path’s end-to-end cloud-based, quantitative approach is able to provide clinical solution in both diagnostics and translational medicine without adding extra load to the current standard of care. Its patented methods and integrated platform combine physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints that can inform treatment selection as well as stratify patients for novel targeted therapies without the need for a training dataset or human intervention. If you're a member of the media, you can contact us at 4DPathPress@svmpr.com. 4D Path Inc., 11 John St., Newton, MA 02459 USA
+ 1 617 558 0010   |   info@4dpath.com   |   Terms and Conditions

Just because you can't see something,
doesn't mean it's not there.

4D Path’s patented precision oncology platform — which has recently been awarded FDA Breakthrough Device Designation — unveils ​previously hidden data to instantly provide more accurate biomarker profiling ​and stratification directly just from H&E WSI biopsy/resection images. ​By eliminating the need for additional tests (e.g. immunohistochemistry, genetic testing) 4D Path’s cloud-based platform accelerates complete, actionable and objective insight leading to expedited and democratized precision medicine for optimized patient care and clinical trials. ​4D Path’s end-to-end cloud-based, quantitative approach is able to provide clinical solution in both diagnostics and translational medicine without adding extra load to the current standard of care. Its patented methods and integrated platform combine physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints that can inform treatment selection as well as stratify patients for novel targeted therapies without the need for a training dataset or human intervention.


   

If you're a member of the media, you can contact us at 4DPathPress@svmpr.com.

4D Path Inc., 11 John St., Newton, MA 02459 USA
+ 1 617 558 0010   |   info@4dpath.com   |   Terms and Conditions